a 2017

BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.

PAVLASOVÁ, Gabriela, Marek BORSKÝ, Veronika SVOBODOVÁ, Kateřina MUSILOVÁ, Kateřina ČERNÁ et. al.

Basic information

Original name

BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.

Authors

PAVLASOVÁ, Gabriela (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Veronika SVOBODOVÁ (203 Czech Republic), Kateřina MUSILOVÁ (203 Czech Republic, belonging to the institution), Kateřina ČERNÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Jitka NOVOTNÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek MRÁZ (203 Czech Republic, belonging to the institution)

Edition

22nd EHA Annual Congress; Madrid, Spain, červen 2017 in Haematologica 2017, 2017

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14740/17:00095680

Organization unit

Central European Institute of Technology

Keywords in English

BCR; CLL; rituximab

Tags

Změněno: 18/3/2018 20:03, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo., BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.

Links

LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1106/2016, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)
Investor: Masaryk University, Category A
MUNI/H/0865/2016, interní kód MU
Name: Coding and Non-coding RNA Networks that Regulate B Cell Receptor Signalling: Implications for Combinatorial Therapy
Investor: Masaryk University, Individual High risk/high gain projects
NV16-29622A, research and development project
Name: VLIV TERAPEUTICKÉ INHIBICE BCR SIGNALIZACE NA GENOVOU EXPRESI U B BUNĚČNÝCH MALIGNIT A JEJÍ PROGNOSTICKÝ A PREDIKTIVNÍ VÝZNAM
692298, interní kód MU
Name: MEDGENET - Medical genomics and epigenomics network (Acronym: MEDGENET)
Investor: European Union, Spreading excellence and widening participation